| Literature DB >> 29332452 |
Bifeng Chen1, Jingdong Wang1, Xiuli Gu2,3, Jingli Zhang1, Jiankun Zhang1, Xianhong Feng4.
Abstract
The -149C>T and -579G>T, 2 single nucleotide polymorphisms in de novo methyltransferase 3B gene promoter, have been previously reported to potentially alter the promoter activity and to influence cancer risk. However, the results from previous studies remain conflicting rather than conclusive. In view of this, we conducted a case-control study and then a meta-analysis to examine the association between these 2 single-nucleotide polymorphisms with risk of lung and gastric cancer in Chinese population. The genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism and confirmed by sequencing. In this case-control study, no significant association with lung or gastric cancer risk was observed for -149C>T, while -579G>T was significantly correlated with the risk of gastric cancer but not lung cancer. Moreover, haplotype analysis showed that haplotype -149T/-579 T, which carried the risk -579 T allele, significantly increased the susceptibility to gastric cancer. However, none of the haplotypes was associated with the risk of lung cancer. The following meta-analysis involved only Chinese population and further confirmed the significant association of -579G>T with gastric cancer but not lung cancer and suggested no significant association between -149C>T and risk of lung or gastric cancer. Collectively, DNMT3B -579G>T polymorphism is associated with gastric cancer risk in Chinese population, and the -579G>T may be used as a genetic biomarker to predict the risk of gastric cancer in Chinese population.Entities:
Keywords: Chinese population; DNMT3B; gastric cancer; lung cancer; meta-analysis; single-nucleotide polymorphism (SNP)
Mesh:
Substances:
Year: 2017 PMID: 29332452 PMCID: PMC5762089 DOI: 10.1177/1533034617740475
Source DB: PubMed Journal: Technol Cancer Res Treat ISSN: 1533-0338
Primers and Restriction Enzymes of DNMT3B Polymorphisms for Genotyping.
| Locus | Location | Primer Sequence (5’-3’) | Annealing Temperature | Product | Enzyme, Digestion Temperature | Digested Bands |
|---|---|---|---|---|---|---|
| -149C>T | In the transcription start site | Forward: GCCACCCTACCACCTCTATTC | 58oC | 153 bp |
| C allele: 153bp |
| Reverse: GGACACTCACTGGGGCTTAG | T allele: 131bp + 22bp | |||||
| -579G>T | In the exon 1B transcription start site | Forward: GCCAACCAAAGGTGGAACA | 57oC | 169 bp |
| G allele: 169bp |
| Reverse: GAGGCACAGGCAGAAAGC | T allele: 104bp+65bp |
Characteristics of Patients With Lung Cancer, Patients With Gastric Cancer, and Normal Controls.
| Variables | Patients With Lung Cancer | Patients With Gastric Cancer | Normal Controls |
|
| |
|---|---|---|---|---|---|---|
| Age, years | ≤60 | 306 (55.6%)c | 252 (54.8%) | 434 (54.3%) | .615 | .855 |
| >60 | 244 (44.4%) | 208 (45.2%) | 366 (45.7%) | |||
| Gender | Male | 373 (67.9%) | 323 (70.3%) | 558 (69.7%) | .451 | .862 |
| Female | 177 (32.1%) | 137 (29.7%) | 242 (30.3%) | |||
| Smoking status | Ever | 150 (27.3%) | 132 (28.8%) | 209 (26.1%) | .639 | .323 |
| Never | 400 (72.7%) | 328 (71.2%) | 591 (73.9%) | |||
| Alcohol status | Ever | 170 (31.0%) | 148 (32.1%) | 237 (29.6%) | .613 | .344 |
| Never | 380 (69.0%) | 312 (67.9%) | 563 (70.4%) | |||
aAge, gender, smoking status, and alcohol status distributions of patients with lung cancer and normal controls were compared using 2-sided χ2 test.
bAge, gender, smoking status, and alcohol status distributions of patients with gastric cancer and normal controls were compared using 2-sided χ2 test.
cValues are represented as number (percentage).
Genotype and Allele Distributions of DNMT3B -149C>T and -579G>T Polymorphisms, and Their Association With the Risk of Lung and Gastric Cancer.
|
| I. Patients With Lung Cancer | II. Patients With Gastric Cancer | III. Normal Controls | HWEa | Logistic Regression, | ||
|---|---|---|---|---|---|---|---|
| Genetic Model | I vs III | II vs III | |||||
| -149C>T | |||||||
| T | 1038 (94.4%) | 884 (96.1%) | 1522 (95.1%) | T vs C | .381, 0.86 (0.61-1.21) | .264, 1.26 (0.84-1.88) | |
| C | 62 (5.6%) | 36 (3.9%) | 78 (4.9%) | ||||
| TT | 490 (89.1%) | 425 (92.3%) | 724 (90.4%) | 0.940 | TT vs TC | .427, 0.86 (0.60-1.24) | .257, 1.28 (0.84-1.95) |
| TC | 58 (10.6%) | 34 (7.5%) | 74 (9.3%) | TT vs CC | .697, 0.68 (0.10-4.82) | .896, 1.17 (0.11-13.0) | |
| CC | 2 (0.3%) | 1 (0.2%) | 2 (0.3%) | TC vs CC | .810, 0.78 (0.11-5.73) | .946, 0.92 (0.08-10.5) | |
| TT vs TC+CC | .398, 0.86 (0.60-1.23) | .255, 1.28 (0.84-1.94) | |||||
| TT+TC vs CC | .707, 0.69 (0.10-4.90) | .909, 1.15 (0.10-12.7) | |||||
| -579G>T | |||||||
| T | 953 (86.7%) | 829 (90.1%) | 1364 (85.3%) | T vs G | .311, 1.12 (0.90-1.40) | .001, 1.58 (1.22-2.04) | |
| G | 147 (13.4%) | 91 (9.9%) | 236 (14.7%) | ||||
| TT | 413 (75.1%) | 374 (81.4%) | 580 (72.5%) | 0.693 | TT vs TG | .302, 1.14 (0.89-1.48) | .001, 1.62 (1.22-2.17) |
| TG | 127 (23.1%) | 81 (17.7%) | 204 (25.5%) | TT vs GG | .749, 1.14 (0.51-2.54) | .161, 2.06 (0.75-5.68) | |
| GG | 10 (1.8%) | 5 (1.0%) | 16 (2.0%) | TG vs GG | .993, 1.00 (0.44-2.26) | .651, 1.27 (0.45-3.58) | |
| TT vs TG+GG | .289, 1.14 (0.89-1.47) | .001. 1.65 (1.25-2.19) | |||||
| TT+TG vs GG | .811, 1.10 (0.50-2.45) | .230, 1.86 (0.68-5.10) | |||||
Abbreviations: CI, confidence interval; HWE, Hardy-Weinberg equilibrium; OR, odds ratio.
aGenotypic frequency of DNMT3B polymorphisms in normal controls were tested for departure from Hardy-Weinberg equilibrium (HWE) using the χ2 test.
bThe P value was calculated using 2-sided χ2 test.
cOR (95% CI) was estimated by logistic regression analysis.
Association Between DNMT3B Haplotypes With Risk of Lung and Gastric Cancer.
| Haplotypea | I. Patients With Lung Cancer | II. Patients With Gastric Cancer | III. Normal Controls | I vs III | II vs III | ||||
|---|---|---|---|---|---|---|---|---|---|
| χ2 |
| OR (95% CI)c | χ2 |
| OR (95% CI)c | ||||
| -149C/-579G | 0.024 | 0.013 | 0.024 | 0.001 | .985 | 1.00 (0.60-1.65) | 3.434 | .068 | 0.54 (0.28-1.05) |
| -149C/-579T | 0.033 | 0.026 | 0.032 | 0.015 | .902 | 1.03 (0.67-1.59) | 0.675 | .411 | 0.81 (0.50-1.33) |
| -149T/-579G | 0.091 | 0.086 | 0.110 | 2.582 | .108 | 0.81 (0.63-1.05) | 3.722 | .054 | 0.76 (0.58-1.00) |
| -149T/-579T | 0.852 | 0.875 | 0.834 | 1.591 | .207 | 1.15 (0.93-1.42) | 7.697 | .006 | 1.40 (1.10-1.77) |
| Global test | 1.000 | 1.000 | 1.000 | 2.450 | .484 | 8.563 | .036 | ||
Abbreviations: CI, confidence interval; OR, odds ratio.
aThe haplotype structure was -149C>T/-579G>T. All haplotypes with frequency <0.01 in both case and control groups would be ignored in analysis.
bThe P value was calculated using 2-sided χ2 test.
cOR (95% CI) was estimated by logistic regression analysis.
Characteristics of Current and Previous Studies in Chinese Population.
| References | Region | Cancer Type | Case (n) | Control (n) | Matching Y/N | Quality Controla Y/N | HWEb | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -149C>T | Total | T/C | TT/TC/CC | Total | T/C | TT/TC/CC | ||||||
| Wang et al[ | Hebei | Gastric cancer | 212 | 417/7 | 205/7/0 | 294 | 573/15 | 279/15/0 | Y | Y | 0.654 | |
| Zhang[ | Jiangsu | Gastric cancer | 156 | 309/3 | 154/1/1 | 156 | 311/1 | 155/1/0 | Y | Y | 0.968 | |
| Hu et al[ | Jiangsu | Gastric cancer | 259 | 516/2 | 257/2/0 | 262 | 521/3 | 259/3/0 | Y | Y | 0.926 | |
| Qiu et al[ | Jiangsu | Gastric cancer | 233 | 462/4 | 229/4/0 | 208 | 412/4 | 204/4/0 | Y | Y | 0.889 | |
| Current study | Hubei | Gastric cancer | 460 | 884/36 | 425/34/1 | 800 | 1522/78 | 724/74/2 | Y | Y | 0.940 | |
| Yang[ | Jilin | Lung cancer | 52 | 99/5 | 47/5/0 | 55 | 107/3 | 52/3/0 | Y | Y | 0.835 | |
| Zhang et al[ | Heilongjiang | Lung cancer | 50 | 97/3 | 48/1/1 | 60 | 118/2 | 58/2/0 | Y | Y | 0.896 | |
| Current study | Hubei | Lung cancer | 550 | 1038/62 | 490/58/2 | 800 | 1522/78 | 724/74/2 | Y | Y | 0.940 | |
| -579G>T | Total | T/G | TT/TG/GG | Total | T/G | TT/TG/GG | ||||||
| Hu et al[ | Jiangsu | Gastric cancer | 259 | 487/31 | 230/27/2 | 262 | 461/63 | 203/55/4 | Y | Y | 0.901 | |
| Zhang et al[ | Heilongjiang | Gastric cancer | 50 | 93/7 | 43/7/0 | 60 | 108/12 | 48/12/0 | Y | Y | 0.389 | |
| Current study | Hubei | Gastric cancer | 460 | 829/91 | 374/81/5 | 800 | 1364/236 | 580/204/16 | Y | Y | 0.693 | |
| Liu et al[ | Heilongjiang | Lung cancer | 174 | 327/21 | 154/19/1 | 135 | 244/26 | 109/26/0 | Y | Y | 0.216 | |
| Zhang et al[ | Heilongjiang | Lung cancer | 98 | 175/21 | 77/21/0 | 105 | 185/25 | 80/25/0 | Y | Y | 0.166 | |
| Current study | Hubei | Lung cancer | 550 | 953/147 | 413/127/10 | 800 | 1364/236 | 580/204/16 | Y | Y | 0.693 | |
Abbreviation: HWE, Hardy-Weinberg equilibrium
aQuality control was conducted when sample of cases and controls was genotyped.
bGenotypic frequencies of -149C>T and -579G>T in normal controls were tested for departure from Hardy-Weinberg equilibrium (HWE) using the χ2 test.
Pooled ORs and 95% CIs in the Meta-Analysis.
| Genetic Model | Heterogeneity Test | Summary OR (95% CI) | Hypothesis Test | Studies (n) | |||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
| |||
| -149C>T and gastric cancer | |||||||
| T vs C | 1.61 | .81 | 0% | 1.25 (0.89-1.76) | 1.28 | .20 | 5 |
| TT vs TC | 0.27 | .99 | 0% | 1.31 (0.92-1.88) | 1.48 | .14 | 5 |
| TT vs CC | 0.38 | .54 | 0% | 0.72 (0.12-4.35) | 0.36 | .72 | 2 |
| TC vs CC | 0.19 | .67 | 0% | 0.68 (0.09-5.04) | 0.37 | .71 | 2 |
| TT vs TC+CC | 0.85 | .93 | 0% | 1.29 (0.90-1.83) | 1.39 | .16 | 5 |
| TT+TC vs CC | 0.37 | .54 | 0% | 0.71 (0.12-4.30) | 0.38 | .71 | 2 |
| -149C>T and lung cancer | |||||||
| T vs C | 0.53 | .77 | 0% | 0.83 (0.60-1.15) | 1.15 | .25 | 3 |
| TT vs TC | 0.65 | .72 | 0% | 0.85 (0.601.21) | 0.90 | .37 | 3 |
| TT vs CC | 0.22 | .64 | 0% | 0.52 (0.10-2.65) | 0.79 | .43 | 2 |
| TC vs CC | 0.39 | .53 | 0% | 0.57 (0.10-3.17) | 0.64 | .52 | 2 |
| TT vs TC+CC | 0.35 | .84 | 0% | 0.83 (0.59-1.17) | 1.03 | .30 | 3 |
| TT+TC vs CC | 0.23 | .63 | 0% | 0.52 (0.10-2.66) | 0.79 | .43 | 2 |
| -579G>T and gastric cancer | |||||||
| T vs G | 1.45 | .48 | 0% | 1.69 (1.36-2.10) | 4.73 | <1×10−5 | 3 |
| TT vs TG | 1.51 | .47 | 0% | 1.76 (1.38-2.24) | 4.57 | <1×10−5 | 3 |
| TT vs GG | 0.01 | .93 | 0% | 2.11 (0.88-5.05) | 1.68 | .09 | 2 |
| TG vs GG | 0.06 | .80 | 0% | 1.19 (0.49-2.91) | 0.39 | .70 | 2 |
| TT vs TG+GG | 1.46 | .48 | 0% | 1.78 (1.41-2.25) | 4.79 | <1×10−5 | 3 |
| TT+TG vs GG | <0.01 | .94 | 0% | 1.89 (0.79-4.51) | 1.43 | .15 | 2 |
| -579G>T and lung cancer | |||||||
| T vs G | 1.46 | .48 | 0% | 1.17 (0.96-1.43) | 1.56 | .12 | 3 |
| TT vs TG | 2.27 | .32 | 12% | 1.22 (0.98-1.52) | 1.74 | .08 | 3 |
| TT vs GG | 0.28 | .60 | 0% | 1.07 (0.50-2.32) | 0.18 | .86 | 2 |
| TG vs GG | 0.67 | .41 | 0% | 0.90 (0.41-1.97) | 0.26 | .79 | 2 |
| TT vs TG+GG | 1.90 | .39 | 0% | 1.21 (0.97-1.50) | 1.71 | .09 | 3 |
| TT+TG vs GG | 0.32 | .57 | 0% | 1.03 (0.48-2.22) | 0.08 | .93 | 2 |
Abbreviations: CI, confidence interval; OR, odds ratio.